Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IKNA

Ikena Oncology Inc

Dec 13 • 12:15PM ET

1.65

Dollar change -0.00
Percentage change -0.30	%

Healthcare • Biotechnology • USA • NASD

Peers: SAGE BPMC BHVN FATE RAPT NERV AFMD ADAP CTMX

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.24	Insider Own	43.40%	Shs Outstand	48.26M	Perf Week	-1.49%
Market Cap	79.87M	Forward P/E	-	EPS next Y	-0.94	Insider Trans	0.00%	Shs Float	27.31M	Perf Month	-4.89%
Income	-59.60M	PEG	-	EPS next Q	-0.27	Inst Own	25.98%	Short Float	0.33%	Perf Quarter	-3.78%
Sales	0.66M	P/S	121.01	EPS this Y	28.07%	Inst Trans	-4.49%	Short Ratio	1.51	Perf Half Y	-5.43%
Book/sh	2.78	P/B	0.59	EPS next Y	20.04%	ROA	-32.72%	Short Interest	0.09M	Perf Year	-18.07%
Cash/sh	2.86	P/C	0.58	EPS next 5Y	-	ROE	-37.08%	52W Range	1.22 - 2.32	Perf YTD	-15.99%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-7.46%	ROI	-42.97%	52W High	-28.66%	Beta	0.50
Dividend TTM	-	Quick Ratio	15.32	Sales past 5Y	280.42%	Gross Margin	-7.13%	52W Low	35.66%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	15.32	EPS Y/Y TTM	23.33%	Oper. Margin	-9755.24%	RSI (14)	40.00	Volatility	3.08% 2.80%
Employees	43	Debt/Eq	0.06	Sales Y/Y TTM	-95.28%	Profit Margin	-9043.85%	Recom	1.50	Target Price	3.00
Option/Short	No / Yes	LT Debt/Eq	0.03	EPS Q/Q	46.88%	Payout	-	Rel Volume	1.52	Prev Close	1.66
Sales Surprise	-	EPS Surprise	17.61%	Sales Q/Q	-100.00%	Earnings	Nov 07 BMO	Avg Volume	60.12K	Price	1.65
SMA20	-2.30%	SMA50	-2.98%	SMA200	3.28%	Trades		Volume	41,216	Change	-0.30%

Date	Action	Analyst	Rating Change	Price Target Change
May-29-24	Downgrade	Wedbush	Outperform → Neutral	$8 → $2
Sep-22-23	Initiated	Wedbush	Outperform	$11
May-04-23	Resumed	H.C. Wainwright	Buy	$18
Dec-23-21	Initiated	H.C. Wainwright	Buy	$25
May-05-21	Resumed	Credit Suisse	Outperform	$30
Apr-26-21	Resumed	Credit Suisse	Outperform	$30
Apr-20-21	Initiated	William Blair	Outperform
Apr-20-21	Initiated	Jefferies	Buy
Apr-20-21	Initiated	Credit Suisse	Outperform	$30

Nov-07-24 08:30AM	Ikena Oncology Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Aug-08-24 04:15PM	Ikena Oncology Reports Second Quarter 2024 Financial Results (GlobeNewswire)
May-29-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) +25.56%
May-28-24 04:42PM	UPDATE Ikena Oncology Announces Strategic Update (GlobeNewswire)
04:15PM	Ikena Oncology Announces Strategic Update (GlobeNewswire)
08:52PM	Loading…
May-13-24 08:52PM	IKNA Stock Earnings: Ikena Oncology Beats EPS for Q1 2024 (InvestorPlace)
04:45PM	Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-10-24 08:00AM	Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum (GlobeNewswire) -5.26%
Mar-12-24 08:00AM	Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 08:00AM	Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-21-24 04:15PM	Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer (GlobeNewswire)
Feb-14-24 09:35AM	Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround (Zacks)
Jan-24-24 09:35AM	Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround (Zacks)
Jan-19-24 06:25AM	Ikena Oncology to lay off 35% of staff (BioPharma Dive) -7.32%
Jan-18-24 04:05PM	Ikena Oncology Outlines Key Priorities and Provides Corporate Updates (GlobeNewswire) -5.20%
07:00AM	Loading…
Nov-09-23 07:00AM	Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results (GlobeNewswire) -67.80%
Nov-07-23 08:00AM	Ikena Oncology to Present at Multiple November 2023 Investor Conferences (GlobeNewswire)
Sep-27-23 09:01AM	Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks)
Sep-05-23 08:00AM	Ikena Oncology to Participate in September 2023 Investor Conferences (GlobeNewswire)
Aug-12-23 08:07AM	Downgrade: Here's How Analysts See Ikena Oncology, Inc. (NASDAQ:IKNA) Performing In The Near Term (Simply Wall St.)
Aug-10-23 09:30AM	Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +8.10%
08:00AM	Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
06:08AM	The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stake (American City Business Journals)
Aug-08-23 08:24AM	Loss-making Ikena Oncology (NASDAQ:IKNA) sheds a further US$11m, taking total shareholder losses to 22% over 1 year (Simply Wall St.)
Aug-07-23 07:00AM	Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction (GlobeNewswire) -7.51%
Jun-20-23 08:50AM	Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why (Zacks)
Jun-05-23 02:59PM	We're Keeping An Eye On Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate (Simply Wall St.)
Jun-02-23 08:50AM	Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-24-23 08:00AM	Ikena Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-16-23 08:29AM	Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts (Simply Wall St.) -12.00%
09:05AM	Loading…
May-15-23 09:05AM	Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:50AM	Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline (GlobeNewswire)
07:45AM	Ikena Oncology Announces $40 Million Underwritten Offering (GlobeNewswire)
06:01AM	Ikena Oncology, Inc.'s (NASDAQ:IKNA) largest shareholders are private equity firms with 46% ownership, institutions own 31% (Simply Wall St.)
May-10-23 05:35PM	Kronos Bio, Inc. (KRON) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:42AM	Why Ikena Oncology (IKNA) Might Surprise This Earnings Season (Zacks)
May-08-23 12:07PM	Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing? (Zacks)
May-04-23 09:00PM	Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar? (Zacks) +7.90% +16.40%
May-03-23 08:50AM	Here's Why Momentum in Ikena Oncology, Inc. (IKNA) Should Keep going (Zacks)
May-02-23 09:29PM	Immatics (IMTX) Moves 27.5% Higher: Will This Strength Last? (Zacks)
Apr-20-23 08:00AM	Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days (GlobeNewswire) -5.22%
Apr-17-23 09:00AM	Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting (GlobeNewswire)
06:48AM	Getting In Cheap On Ikena Oncology, Inc. (NASDAQ:IKNA) Is Unlikely (Simply Wall St.)
Mar-14-23 08:15AM	Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-07-23 08:00AM	Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting (GlobeNewswire) +12.95%
Mar-06-23 08:00AM	Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma (GlobeNewswire)
Mar-01-23 07:13AM	Ikena Oncology (NASDAQ:IKNA) shareholders have endured a 43% loss from investing in the stock a year ago (Simply Wall St.)
Feb-28-23 08:00AM	Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Dec-22-22 07:13AM	Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-19-22 04:30PM	Ikena Oncology Appoints Owen Hughes as Board Chair (GlobeNewswire)
Nov-28-22 12:11PM	Ikena Oncology Announces New Cancer Program, Shelves Early Asset For Colorectal Cancer (Benzinga)
08:00AM	Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update (GlobeNewswire)
Nov-22-22 07:30AM	Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) +5.45%
Nov-11-22 10:05AM	Ikena Oncology Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 09:00AM	Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma (GlobeNewswire)
Nov-07-22 09:25AM	Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:48AM	UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
08:05AM	Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-26-22 07:30AM	Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance (GlobeNewswire) +6.97%
Oct-18-22 07:30AM	Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway (GlobeNewswire)
Oct-05-22 08:05AM	Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (GlobeNewswire) -9.73%
Sep-22-22 06:25AM	Investors one-year losses grow to 71% as the stock sheds US$33m this past week (Simply Wall St.) -8.95%
Sep-06-22 07:30AM	Ikena Oncology to Participate in September 2022 Investor Conferences (GlobeNewswire)
Aug-12-22 07:41AM	Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers (Simply Wall St.)
Aug-11-22 08:45AM	Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-14-22 10:43AM	How Much Of Ikena Oncology, Inc. (NASDAQ:IKNA) Do Institutions Own? (Simply Wall St.)
Jul-06-22 07:00AM	Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022 (GlobeNewswire) +6.38%
Jun-22-22 07:00AM	Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma (GlobeNewswire) +5.48%
Jun-14-22 09:13AM	We Think Ikena Oncology (NASDAQ:IKNA) Can Afford To Drive Business Growth (Simply Wall St.)
May-18-22 07:00AM	Ikena Oncology to Participate in Spring 2022 Investor Conferences (GlobeNewswire) -7.23%
May-15-22 08:41AM	Ikena Oncology, Inc. (NASDAQ:IKNA) Just Reported Earnings, And Analysts Cut Their Target Price (Simply Wall St.)
May-13-22 08:28AM	The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma (Zacks)
May-12-22 08:35AM	Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-11-22 08:44AM	Is a Surprise Coming for Ikena Oncology (IKNA) This Earnings Season? (Zacks) -16.00%
07:32AM	5 Biotech Stocks Set to Outpace Q1 Earnings Estimates (Zacks)
May-02-22 07:00AM	Ikena Oncology and Vall dHebron Institute of Oncology Announce Research & Development Collaboration (GlobeNewswire)
Apr-28-22 07:00AM	Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting (GlobeNewswire) -10.49%
Apr-13-22 07:00AM	Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development (GlobeNewswire) +7.35%
Apr-12-22 02:01PM	10 Best Micro-Cap Stocks to Buy According to Hedge Funds (Insider Monkey)
Mar-28-22 05:37PM	Ikena Oncology (NASDAQ:IKNA shareholders incur further losses as stock declines 16% this week, taking one-year losses to 79% (Simply Wall St.)
Mar-17-22 07:00AM	Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update (GlobeNewswire) +23.30%
Mar-07-22 04:30PM	Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-01-22 07:00AM	Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference (GlobeNewswire)
Feb-03-22 04:35PM	Top 10 Stock Picks of Samuel Isalys OrbiMed Advisors (Insider Monkey) -14.76%
Jan-26-22 07:00AM	Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors (GlobeNewswire)
Dec-24-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-23-21 06:05AM	Here's Why We're Not Too Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Situation (Simply Wall St.)
Dec-18-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-17-21 08:00AM	Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies (PR Newswire) -5.61%
Dec-08-21 07:00AM	Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer (GlobeNewswire) +13.73%
Nov-12-21 07:00AM	Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175 (GlobeNewswire)
Nov-10-21 07:00AM	Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) +10.94%
Nov-04-21 07:00AM	Ikena Oncology to Participate in November 2021 Virtual Investor Conferences (GlobeNewswire)
Nov-02-21 08:00AM	Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930 (GlobeNewswire) +8.93%
Oct-07-21 09:00AM	Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment (GlobeNewswire) +9.21%
Oct-01-21 08:15AM	Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (GlobeNewswire)
Sep-02-21 07:00AM	Ikena Oncology to Participate in September 2021 Virtual Investor Conferences (GlobeNewswire)

Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IKNA

Ikena Oncology Inc

Upgrade your FINVIZ experience